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Abstract
Background: In spite of high prevalence and clinical relevance of leukoaraiosis (LA), its pathophysiology is still
incompletely understood. Theories of ischaemic genesis and a leaky blood–brain barrier are contradictory yet could
share a common denominator–endothelial dysfunction (cerebral, systemic or both), which has not been studied
thoroughly in LA.
Methods: Thirty patients with LA (58 years (SD 7)) and 30 gender- and age-matched controls without LA (55 years
(SD 6)) were recruited. The vascular risk factors (VRF) were identical in both groups. Cerebral endothelial function
was determined by cerebrovascular reactivity to L-arginine (CVR). Systemic endothelial function was determined by
flow-mediated dilatation (FMD) of the brachial artery after hyperaemia. All participants underwent a brain MRI to
search for radiological signs of LA that was classified according to the Fazekas score. Linear regression was used to
explore the correlation between CVR and FMD in patients with LA. A 95 % confidence interval was used. For any
statistical test used in the study, p ≤ 0.050 was regarded as statistically significant.
Results: We found a marked and significant decrease in both CVR (9.6 % (SD 3.2) vs. 15.8 % (SD 6.1), p < 0.001) and
FMD (4.8 % (SD 3.1) vs. 7.4 % (SD 3.8), p = 0.004) in LA patients compared to controls. Both CVR (7.4 % (SD 3.1) vs.
12.2 % (SD 2.6), p = 0.001) and FMD (3.0 % (SD 2.2) vs. 6.4 % (SD 3.1), p = 0.011) were significantly decreased in LA
subgroup Fazekas 3 compared to subgroup Fazekas 1. CVR and FMD significantly positively correlated (b = 0.192,
95 % CI = 0.031–0.354, p = 0.02).
Conclusions: The results of our pilot study suggest that patients with LA have a significant impairment of both
cerebral and systemic endothelial function that is larger than could be expected based on present VRF. Endothelial
dysfunction increases in parallel with LA severity and correlates between cerebral and systemic arterial territory.
Overall, our results suggest a so far unknown “intrinsic” generalised endothelial dysfunction in patients with LA that
could be involved in LA pathophysiology. This interesting issue needs to be confirmed in larger samples since it
could help better understand the mechanisms underlying LA.
Background
It is well known that leukoaraiosis (LA) is associated
with cognitive decline and a higher risk of stroke and
death [1]. Given the clinical relevance of LA [2–5], re-
cent years have shown a growing interest in its patho-
physiology, which is at present incompletely understood.
The concepts of ischaemic genesis [6, 7] and a defective
blood–brain barrier [8, 9] seem to oppose each other.
Nevertheless, the cerebral endothelial dysfunction might
explain both; however, recent studies have not clearly re-
solved the issue [10, 11]. Thus, in the present studies,
the harmful effects of vascular risk factors (VRF) on
endothelial function have not been delineated from pos-
sible primary endothelial dysfunction in patients with
LA. What is more, the relation between cerebral and
systemic endothelial function in LA is presently un-
known as well.
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It has been shown that L-arginine increases cerebral
blood flow after intravenous infusion in animal studies as
well as in humans [12, 13]. Exogenously derived L-
arginine increases the release of nitrous oxide (NO) from
the cerebral endothelium, being one of the key vasodilata-
tors. The cerebrovascular reactivity to L-arginine (CVR) is
reported to be a reliable marker for cerebral endothelial
function [14, 15]. Hence, the method seems to be useful
to investigate CVR in patients with LA. Nevertheless, the
method has not yet been used to determine cerebral endo-
thelial function in LA. On the other hand, the flow-
mediated dilatation (FMD) is a widely used method for
the evaluation of systemic endothelial function [16], which
has also been applied in LA albeit without concurrently
studying cerebral endothelial function [17]. Contrary to
previous studies, we aimed at estimating both systemic
and cerebral endothelial function in patients with LA.
The aim of this study was to investigate the CVR and
FMD in patients with LA. It is well known that several
VRF, which are usually found in patients with LA, affect
cerebral and systemic endothelial function themselves
[18]. In order to determine the role of primary endothe-
lial impairment in LA and to eliminate the confounding
effects of VRF on LA, we compared CVR and FMD in
LA patients with that of patients with similar VRF with-
out LA and tried to find out whether and how CVR and
FMD correlate in patients with LA.
Methods
The study was performed in two age- and gender-
matched groups of patients sharing identical VRF. The
inclusion age was between 45 and 65 years. The LA
group consisted of patients from neurology outpatient
clinic with visible LA in brain magnetic resonance im-
aging (MRI). All patients in LA group with a history of
stroke/minor stroke or transient ischaemic attack (TIA)
had the index event at least 6 months before the inclu-
sion. The control group consisted of patients who had
undergone brain MRI for other reasons and did not have
any radiological signs of LA. The study was approved by
the National Medical Ethics Committee of the Republic
of Slovenia and all subjects gave written informed con-
sent before inclusion. All the procedures followed were
in accordance with institutional guidelines.
The VRF were evaluated based on a standardized inter-
view, encompassing patient history, neurological examin-
ation, body mass index determination, laboratory tests
and electrocardiography (ECG). The laboratory tests con-
sisted of fasting total cholesterol, high-density lipoprotein
(HDL), low-density lipoprotein (LDL), triglycerides (TG)
and glucose. Only subjects with normal fasting serum glu-
cose levels (<6.1 mmol/l) based on regular general practice
serum glucose measurements, were included. Patients
with diabetes were not included in the study. Additionally,
laboratory tests included vitamin B12, folic acid and thy-
roid stimulating hormone (TSH) in order to exclude other
possible secondary causes of cognitive impairment. Sub-
jects with a known source of cardiogenic embolism based
on ECG were excluded from the study.
The colour-coded duplex sonography and power
Doppler sonography of the carotid and vertebral arteries
were performed in all participants. The intima-media
thickness (IMT) was measured bilaterally according to
the Mannheim intima-media consensus on the far wall
of the common carotid artery [19]. Our final IMT value
was based on the mean value of three maximal IMT
measurements. Eventual plaques were classified into five
standard categories according to their echogenicity. All
ultrasonographic measurements were done in a blind
fashion by the same experienced ultrasonographer un-
aware of a particular participant’s status.
A brain MRI without contrast medium was performed
in all subjects to look for radiological signs of LA (Phi-
lips 1.5T Achieva, coil SENSE-NV-16, Eindhoven, the
Netherlands). The scans were systematically evaluated
for signs of LA in a double-blind fashion employing two
experienced neuroradiologists. The following sequences
were used: T2 weighted sequence in the sagittal and
transversal plane, echo time (TE) = 100 ms, repetition
time (TR) = short, slice thickness 5 mm, matrix 512 ×
512; T1 weighted sequence in the transversal plane,
TR = 450 ms, TE = 15 ms, slice thickness 5 mm,
matrix 320 × 320; FLAIR sequence in the transversal
plane, TR = 1100 ms, TE = 140 ms, slice thickness
3 mm, matrix 256 × 256; time of flight (TOF) se-
quence, TE = out of phase, TR = short, matrix 560 ×
560; diffusion imaging, b = 0, b = 500, b = 1000 and an
apparent diffusion coefficient (ADC) map. Leukoaraio-
sis was classified into four subgroups according to the
Fazekas score: 0–none, 1–mild punctuate hyperinten-
sive lesions, 2–partly confluent hyperintensive lesions
and 3–extensive confluent hyperintensive lesions [20].
The study of endothelial function took place in a quiet
room under constant conditions between 8.00 a.m. and
11.00 a.m. after a fasting period of at least 10 h. Flow-
mediated dilatation of the right brachial artery was stud-
ied according to the recommendations of the Inter-
national Brachial Artery Reactivity Task Force prior to
infusion of L-arginine in order to avoid a possible influ-
ence of L-arginine on the determination of FMD [21]. A
high-resolution B mode ultrasound system (ALOKA
Alpha 10, Tokyo, Japan) with a 10 MHz linear array
transducer was used. The patients rested in the supine
position for 10 min prior to hemodynamic measure-
ments. The right brachial artery was scanned in the lon-
gitudinal section 20 to 100 mm above the antecubital
fossa to find the clearest images of the anterior and pos-
terior wall layers. The end-diastolic mean arterial
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diameter was measured at the end of the diastole period,
incident with the R-wave on the simultaneously recorded
ECG. At least three cardiac cycles were analyzed for
each scan and the measurements averaged. The flow vel-
ocity was measured at a fixed incident angle of 68° to
the vessel with the range gate of 1.3 mm located in the
centre of the artery. The baseline blood flow was esti-
mated by multiplying the velocity time integral of the
Doppler flow signal (corrected for the incident angle) by
the vessel cross-sectional area. A hyperaemic flow in-
crease was induced by inflation of a blood pressure cuff
placed around the forearm to a pressure of 300 mmHg
for 4.5 min. The hyperaemic flow was recorded for the
first 15 to 20 s and diameter measurements took place
60 to 90 s after cuff deflation. The FMD was expressed
as the percentage change in the artery diameter after re-
active hyperaemia relative to the baseline scan.
After a 15 min pause, the cerebrovascular reactivity to
L-arginine (CVR) was determined. In the preparatory
phase, each patient rested for 15 min to achieve a suffi-
ciently relaxed state. The experiment consisted of a
15 min baseline period, a 30 min intravenous infusion of
100 ml of 30 % L-arginine solution and a 15 min interval
after the cessation of L-arginine application. The pa-
tients were instructed to breathe normally and encour-
aged not to doze off. The mean arterial velocity (vm) was
recorded bilaterally in the trunks of both middle cerebral
arteries (MCA) through the temporal acoustic windows
at a depth of 50 to 54 mm. Two 2 MHz probes were
prevented from moving by a mechanical probe holder
(DopplerBox, Sipplingen, Germany). Throughout the
procedure, the mean arterial blood pressure (MAP) and
heart rate (HR) were measured continuously using non-
invasive plethysmography (Colin CBM-7000, Komaki-
City, Japan). The plethysmograph was connected directly
to the Doppler sonograph. The partial pressure of ex-
haled CO2 (CO2) was measured by an infrared capno-
graph (Draeger, Capnodig, Lübeck, Germany), which
was connected to a breathing mask and the Doppler
sonograph. TCD Multi-Dop X4 (DWL, Sipplingen,
Germany) software was used to determine vm during the
10 min rest interval and the 10 min interval following
the cessation of L-arginine infusion. The vm was calcu-




The CVR was calculated according to the equation:
CVR ¼ ðvmsvmrÞ=vmr:
The vms denotes the mean arterial velocity after L-
arginine infusion and the vmr the mean arterial velocity
at rest.
Mean arterial pressure, HR and CO2 were calculated
for the same intervals as vm using TCD software. All
measurements to determine FMD and CVR were carried
out by the single experienced investigator who was blind
to the patients’ characteristics. The repeatability of TCD
measurements of vm upon which CVR is calculated was
95.8 %.
The following variables were statistically analyzed by
statistical software SPSS 20.0.0: FMD, baseline diameter
of the right brachial artery (diamb), posthyperaemic
diameter of the right brachial artery (diamp), vm, MAP,
HR, CO2 and CVR. The paired t-test was used to com-
pare diamb and diamp and additionally vm, MAP, HR
and CO2 before and after intravenous infusion of L-
arginine for each group separately. The unpaired t-test
was used to compare diamb, diamp, FMD, vm, MAP, HR,
CO2 and CVR-L-arg between patients with LA and
those without LA. One-way ANOVA with Bonferroni
correction was used to compare FMD, vm, MAP, HR,
CO2 and CVR between the subgroups of LA. Fisher’s
exact test was used to examine the significance of the as-
sociation between categorical variables. Linear regression
was used to explore the correlation between CVR and
FMD in patients with LA. A 95 % confidence interval
(CI) was used. For any statistical test used in the study,
p ≤ 0.050 was regarded as statistically significant.
Results
The baseline characteristics of patients in both groups
are shown in Table 1. The LA group consisted of 30 pa-
tients with LA divided into three subgroups according
to the Fazekas score, each containing 10 patients
(33.3 %). In only 3 (all Fazekas score 2) out of 30 pa-
tients with LA meticulous evaluation for signs of LA
yielded slightly asymmetric distribution of LA lesions
between both cerebral hemispheres. However, it was not
of such amplitude to ascribe a different Fazekas score to
both cerebral hemispheres. The control group consisted
of 30 patients with similar VRF without LA. The reasons
for performing MRI in control patients are outlined in
Table 2. The results of laboratory work-up did not show
any differences between the LA group and control group
(Table 3).
Within each group, the diamp rose significantly over the
diamb in all participants (LA group: diamb = 4.37 mm
(standard deviation (SD) 0.94), diamp = 4.58 mm (SD
1.01), p < 0.01; control group: diamb = 4.44 mm (SD 0.91),
diamp = 4.76 mm (SD 0.94), p < 0.01). The FMD was
markedly and significantly diminished in patients with LA
compared to patients with similar VRF without LA (4.8 %
(SD 3.1) vs. 7.4 % (SD 3.8), p = 0.004; Fig. 1a). The FMD
was markedly and significantly diminished in the sub-
group Fazekas 3 compared to the subgroup Fazekas 1
(3.0 % (SD 2.2) vs. 6.4 % (SD 3.1), p = 0.01; Fig. 1b).
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While the resting vm and that after L-arginine infusion
were moderately albeit significantly higher in control
group compared to LA group, resting MAP, HR and
CO2 did not differ between the two groups (Table 4).
The vm significantly increased after L-arginine infusion
in both LA group (p = 0.002) and control group (p <
0.001) (Table 4). The MAP after L-arginine infusion
(MAPs) rose marginally albeit significantly over MAP at
rest (MAPr) in LA group (p = 0.03) and control group
(p = 0.01) (Table 4). The HR after L-arginine infusion
(HRs) rose moderately and significantly over HR at
rest (HRr) in LA group (p = 0.002) and control group
(p < 0.001) (Table 4). The CO2 after L-arginine infu-
sion (CO2s) did not change significantly compared to
CO2 at rest (CO2r) in LA group (p = 0.19) and control
group (p = 0.40) (Table 4).
The CVR was markedly and significantly lower in pa-
tients with LA compared to patients with similar VRF
without LA (9.6 % (SD 3.2) vs. 15.8 % (SD 6.1), p <
0.001; Fig. 2a). Two out of 3 patients with asymmetric
distribution of LA (all belonging to the Fazekas 2 score)
expressed modestly lower CVR in the hemisphere with
more pronounced LA. However, none of them had sig-
nificant carotid disease. Patients with Fazekas 3 score
had significantly and markedly lower CVR compared to
patients with Fazekas 1 score (7.4 % (SD 3.1) vs. 12.2 %
(SD 2.6), p = 0.001; Fig. 2b) and Fazekas 2 score as well
(9.2 % (SD 1.9), p = 0.008; Fig. 2b). Linear regression
showed a significant positive correlation between CVR
and FMD in patients with LA (b = 0.192, 95 % CI =
0.031–0.354, p = 0.02; Fig. 3). In all patients we observed
the increase in both posthyperaemic brachial artery
diameter (FMD) and vm after L-arginine infusion (CVR).
Discussion
The main findings of our study are significantly dimin-
ished CVR and FMD in LA patients compared to pa-
tients with identical VRF but without LA. Moreover,
CVR and FMD correlated positively in patients with LA.
Furthermore, within the LA group, CVR was signifi-
cantly lower in Fazekas 3 patients compared to Fazekas
1 and even Fazekas 2 patients, whereas FMD was signifi-
cantly lower in Fazekas 3 compared to Fazekas 1 pa-
tients. Overall, our results suggest that in patients with
LA both cerebral and systemic endothelial functions are
impaired to the degrees that are much higher than could
Table 1 Baseline characteristics and vascular risk factors in patients with leukoaraiosis (LA) and control group
LA group (n = 30) Control group (n = 30) p-value
Age 58 years (SD 7) 55 years (SD 6) 0.08
Men 17 (56.7 %) 20 (66.7 %) 0.60
Current smoker 5 (16.7 %) 5 (16.7 %) 0.64
Hypertension 19 (63.3 %) 16 (53.3 %) 0.60
Dyslipidemia 13 (43.3 %) 16 (53.3 %) 0.61
Minor stroke/TIA 13 (43.3 %) 0 (0.0 %) <0.01
Lacunar infarction 9 (30.0 %) 0 (0.0 %) <0.01
Major ischaemic infarction 1 (3.3 %) 1 (3.3 %) 0.45
Focal neurological deficits 13 (43.3 %) 4 (13.3 %) 0.04
Gait disturbance 12 (40.0 %) 2 (6.7 %) 0.01
Carotid plaques 16 (53.3 %) 10 (33.3 %) 0.19
Ischaemic heart disease 3 (10.0 %) 2 (6.7 %) 0.60
Antihypertensive therapy 19 (63.3 %) 15 (50.0 %) 0.44
Statin therapy 14 (46.7 %) 9 (30.0 %) 0.29
Antiplatelet therapy 20 (66.7 %) 7 (23.3 %) <0.01
Systolic blood pressure 145.6 mmHg (SD 20.9) 140.1 mmHg (SD 15.0) 0.25
Diastolic blood pressure 88.7 mmHg (SD 10.1) 84.2 mmHg (SD 8.9) 0.07
Body mass index 27.8 kg/m2 (SD 4.4) 29.0 kg/m2 (SD 5.4) 0.37
Intima-media thickness 0.74 mm (SD 0.11) 0.72 mm (SD 0.11) 0.52
TIA indicates transient ischaemic attack; SD standard deviation
Table 2 Reasons for performing MRI in control patients
Condition Number of patients
Focal neurological deficit 4 (13.3 %)
Symptomatic CVD 1 (3.3 %)
Headache 7 (23.3 %)
Extraaxial benign tumour 1 (3.3 %)
ENT reason (vertigo, hearing loss) 17 (56.7 %)
CVD indicates cerebrovascular disease; ENT ear, nose, throat
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be expected based on present VRF. These results seem
to reveal a so far unreported, more than expected add-
itional impairment of cerebral endothelial function
alongside with systemic endothelial function.
Flow-mediated dilatation had been reported to be di-
minished in patients with LA in previous studies [13, 22,
23] which is in concordance with our findings. Similarly,
Pretnar-Oblak et al. [24, 25] and Kim et al. [26] found
additionally impaired FMD in patients with lacunar in-
farctions (LI) compared to patients with similar VRF
without LI. To the best of our knowledge, this is the first
published study applying CVR to evaluate cerebral endo-
thelial function and comparing it to FMD in LA. Since
endothelial dysfunction of the non-cerebral [15, 27] as
well as cerebral arteries [25] in patients with VRF had
been already proven, a diminished CVR was expected in
both groups. What is intriguing, though, is that our
study showed additionally impaired CVR in LA. This
may reflect additional or even primary impairment of
cerebral endothelial function in LA, regardless of the
presence of VRF. However, this is contradictory to the
results of a former study of our group, where patients
with LI did not show any additional impairment of cere-
bral endothelial function in comparison to patients with
similar VRF but no LI [25]. Although LA and LI share
some common characteristics and are both part of a
wider spectrum, namely cerebral small vessel disease,
one should keep in mind the fact that LA and LI are
Table 3 Results of laboratory work-up in patients with leukoaraiosis and control group
LA group Control group p-value
Serum glucose 5.6 mmol/l (SD 1.9) 5.1 mmol/l (SD 0.7) 0.23
Total cholesterol 4.8 mmol/l (SD 1.2) 5.2 mmol/l (SD 0.9) 0.10
HDL 1.2 mmol/l (SD 0.3) 1.3 mmol/l (SD 0.3) 0.19
LDL 2.9 mmol/l (SD 1.0) 3.1 mmol/l (SD 0.9) 0.33
TG 1.5 mmol/l (SD 1.2) 2.2 mmol/l (SD 1.5) 0.08
Vitamin B12 256.9 pmol/l (SD 58.8) 291.5 pmol/l (SD 100.1) 0.27
Folic acid 18.1 nmol/l (SD 8.0) 18.1 nmol/l (SD 5.5) 0.99
TSH 1.3 mU/l (SD 0.7) 1.4 mU/l (SD 0.8) 0.73


















Fig. 1 Flow-mediated dilatation (FMD) distribution in control group
and leukoaraiosis (LA) group (a) and in the subgroups of LA (b). SD
indicates standard deviation
Table 4 Absolute values of parameters before and after
L-arginine infusion in patients with leukoaraiosis (LA) and
control group
Parameter LA group Control group p-value
vmr 53.2 cm/s (SD 14.1) 63.0 cm/s (SD 8.1) 0.002
vms 57.3 cm/s (SD 18.3) 72.9 cm/s (SD 9.5) <0.001
MAPr 103.5 mmHg (SD 19.4) 101.5 mmHg (SD 9.9) 0.63
MAPs 106.5 mmHg (SD 20.0) 106.1 mmHg (SD 12.0) 0.93
HRr 64/min (SD 13) 62/min (SD 12) 0.63
HRs 71/min (SD 12) 70/min (SD 14) 0.85
CO2r 19.1 mmHg (SD 2.8) 20.8 mmHg (SD 5.5) 0.13
CO2s 18.6 mmHg (SD 3.1) 21.1 mmHg (SD 5.4) 0.05
CO2r indicates partial pressure of carbon dioxide at rest; CO2s partial pressure of
carbon dioxide after L-arginine infusion, HRr heart rate at rest, HRs heart rate after
L-arginine infusion, MAPr mean arterial pressure at rest, MAPs mean arterial
pressure after L-arginine infusion, SD standard deviation, vmr mean flow velocity
in middle cerebral arteries at rest, vms mean flow velocity in middle cerebral
arteries after L-arginine infusion
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different entities. The differences in CVR between LA
and LI could possibly be explained by the greater extent
of rarefaction of brain white matter in the former. The
additionally lower CVR in LA compared to LI, regardless
of the presence of VRF, could reflect the idea of the pri-
mary endothelial dysfunction in LA.
Several authors have studied the CVR in stroke pa-
tients, but the results have been contradictory. Some
have described lower CVR after stroke in comparison to
healthy subjects [14, 25, 28], whereas others have found
an increase in CVR [29]. It is known that several mecha-
nisms are involved in the pathogenesis of stroke, so it is
possible that patient selection was crucial to the hetero-
geneity of the results. Micieli et al. included patients
with symptomatic internal carotid artery stenosis [28,
30], whereas Žvan et al. included patients with large
MCA territory infarctions [14]. Pretnar-Oblak et al. in-
cluded patients with LI [25] and Zimmermann et al. a
rather undefined group of patients with smaller infarc-
tions and transient ischaemic attacks [29]. Interestingly,
the CVR was enhanced in patients with cerebral auto-
somal dominant arteriopathy with subcortical infarctions
and leukoencephalopathy (CADASIL) compared to
healthy controls [11], which is contradictory to our re-
sults. In our study, a homogeneous group of patients
with ischaemic LA was included regarding the clear
presence of similar VRF, which makes the probability of
other aetiologies of LA very unlikely but still possible.
The response to L-arginine in patients with LA is
complex. It is well known that the endothelial enzyme
nitric oxide synthase (NOS III) uses L-arginine as a pre-
cursor for the synthesis of NO [31], which is the main
vasodilatator and blood pressure regulator [32]. Vascular
risk factors suggest that patients with LA have a reduced
synthesis and/or increased oxidative breakdown of NO
[27, 33]. It has been shown in animal studies that adap-

















Fig. 2 Cerebrovascular reactivity to L-arginine (CVR) distribution in
control group and leukoaraiosis (LA) group (a) and in the subgroups






















Fig. 3 Linear regression showing positive correlation between
cerebrovascular reactivity to L-arginine (CVR) and flow-mediated
dilatation (FMD) (a) and the display of regression standardised
residuals (b) in patients with leukoaraiosis
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regulation [34] and an increase in NO production [35].
Therefore, one expects to find increased response of
cerebral arterioles to L-arginine in acute ischemia. How-
ever, in LA there is chronic ischemia [36] with rarefac-
tion of brain white matter, sometimes referred to as
“incomplete infarction” with putative quantitative endo-
thelial loss, which also means the loss of NOS III. This
would explain lower response of cerebral arterioles to L-
arginine in LA. On the other hand, studies have been
published supporting the role of blood–brain barrier
dysfunction in the pathogenesis of LA [8, 9]. The hy-
potheses of chronic ischemia and a leaky blood brain
barrier are not mutually exclusionary since they could be
elegantly coupled through cerebral endothelial dysfunc-
tion, which could be an initial (primary) event in the
pathophysiological cascade leading to LA. This could
offer additional basis for further clarifying the putative
role of genetic polymorphisms and their neuropatho-
logical correlations in LA [37, 38].
The relation between FMD and CVR in patients with
LA has not been studied thoroughly thus far. Albeit
employing different methodology, cerebral and systemic
endothelial dysfunction positively correlated in a study
in CADASIL patients [39]. If FMD and CVR truly cor-
relate in LA this may offer possibilities for a simplified
estimation of cerebral endothelial function in these pa-
tients on the basis of performing solely FMD, which,
contrary to complicated and rather inconvenient CVR, is
a non-invasive, reasonably easy-to-perform and safe
method for the evaluation of endothelial function. From
the clinical standpoint, our study may offer a back-
ground for further intervention studies aiming at enhan-
cing endothelial function in LA. Whether this reflects in
any significant improvement of clinical picture, particu-
larly cognitive domain is a question to be studied in fur-
ther studies.
It is well known that endothelial dysfunction is a sig-
nificant pathological condition implicated in the patho-
physiology of several vascular disorders. It can never be
regarded solely as a surrogate marker of a disease but in-
stead as an “active player” in the pathophysiological
mechanisms. We found additionally impaired cerebral
and systemic endothelial function in LA patients to a de-
gree not expected on the basis of VRF alone. Not to
overlook is our finding that the stage of LA according to
the Fazekas score correlates with the degree of endothe-
lial dysfunction. In our view, additional endothelial dys-
function to the degree unexpected solely on the basis of
VRF may be implicated in the pathophysiology of LA.
There are numerous articles showing or suggesting the
presence of impaired endothelial function as a cause or
contributor to small vessel disease in general and leukoar-
aiosis in particular [40–47]. However, in the listed studies
neither cerebral nor systemic endothelial functions have
been studied together. Also the relations of cerebral and
systemic endothelial dysfunction to the severity of LA and
the relation between cerebral and systemic endothelial
dysfunction still need to be further researched.
One of our study’s limitations is a small number of in-
vestigated subjects as a whole, and particularly in view of
10 patients each per Fazekas scores 1, 2 and 3. With a
small sample like this we cannot exclude the possibility of
false positive results, so they need to be confirmed in lar-
ger samples. In light of this, the association between FMD
and CVR in our LA patients is weak, but despite such a
small number of participants, already significant. The
strength of our study lies in the fact that we included a ra-
ther homogenous group of relatively young patients with
similar VRF, presumably being at initial or moderate
stages of LA, which may offer further opportunities for
intervention. Nevertheless, it is clear from our data that
LA is clinically significant in our patients. The history of
stroke, the presence of gait disturbances and focal neuro-
logical signs were significantly more frequent in LA group.
However, our findings support the hypothesis of an under-
lying possibly “intrinsic” primary cerebral and systemic
endotheliopathy in patients with LA.
Conclusions
To summarise, our pilot study revealed diminished CVR
and FMD correlating positively in patients with LA com-
pared to patients with similar VRF but without LA. This
may reflect “intrinsic” generalised endothelial dysfunc-
tion regardless of VRF in patients with LA, which could
be the initial, primary event in its pathophysiology. How-
ever, since this is a preliminary study the results need to
be confirmed in larger samples in order to help better
understand the mechanisms underlying LA. This may
offer streamlined opportunities for future studying of
clinical interventions aiming at enhancing endothelial
function in patients with LA.
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